CoChat

Changing Nomenclature for PBC: From ‘Cirrhosis’ to ‘Cholangitis’

Open access
Beuers, Ulrich, Gershwin, Eric M, Gish, Robert G, Invernizzi, Pietro, Jones, David E J, Lindor, Keith, Ma, Xiong, Mackay, Ian R, Parés, Albert, Tanaka, Atsushi, Vierling, John M, Poupon, Raoul · 2015 · American Journal of Gastroenterology
Cited by 47

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

The disease entity today widely called ‘primary biliary cirrhosis’ was first described by Addison & Gull in 1851 (1) and Hanot in 1876 (2). One hundred years after its first description, MacMahon & Thannhauser proposed the term ‘xanthomatous biliary cirrhosis’ for this disease based on the typical xanthoma formation with accumulation of cholesterol esters in the skin around the eyes in association with inflammatory destruction of small intrahepatic bile ductules leading to a biliary type cirrhosis (3). Xanthoma formation, however, is not a very common sign in this disorder. This may be the reason why the term ‘primary biliary cirrhosis’, proposed one year later for the same disorder by Ahrens et al., (4) gained wider acceptance when most patients were presenting with advanced liver disease. Dame Sheila Sherlock, already in 1959, opposed the term ‘primary biliary cirrhosis’ as many of her patients were free of cirrhosis at the time of diagnosis and the mean survival was 5 and a half years (3–11) even for the fatal cases, whereas many asymptomatic patients would survive more than 10 years (5). The term ‘primary biliary cirrhosis’ remained an issue of concern as reflected by the name change proposal of Rubin, Schaffner and Popper in 1965 with their paper ‘Primary biliary cirrhosis—Chronic non-suppurative destructive cholangitis’ (6). S. Sherlock wisely commented on this new name: ‘‘…a better one, although it is unlikely that it will replace the more popular, although inaccurate, one of primary biliary cirrhosis’’ (7). She was right, again. And even 40 years later, the European (8) and American (9) Clinical Practice Guidelines still used the term ‘primary biliary cirrhosis’ even though it was an anachronism and did not accurately reflect the natural history of disease in the vast majority of patients as it is today. The early diagnosis of primary biliary cirrhosis has dramatically improved with the more accurate measurements of markers of cholestasis and improvements in the detection of the classic serologic hallmark, anti-mitochondrial antibodies. Furthermore, the prognosis has dramatically improved with the introduction of orthotopic liver transplantation in the 1970s and 1980s, and of ursodeoxycholic acid (UDCA, 13–15 mg/kg daily) treatment in the 1980s and 1990s. Today, two out of three patients diagnosed with primary biliary cirrhosis and treated with UDCA have an expected survival not different from the general population and only a minority will ever develop cirrhosis. The pathogenesis of primary biliary cirrhosis remains enigmatic although enormous progress has been made in unravelling genetic, immunological and pathophysiological molecular mechanisms involved (10, 11, 12, 13). This has also led to new therapeutic approaches which are now under evaluation (14, 15). On 23–24 May, 2014, the 2nd European Association for the Study of the Liver (EASL) Monothematic Conference on Primary Biliary Cirrhosis took place in Milan, Italy. On this occasion, patient representatives from the UK and Germany, Robert Mitchell-Thain and Ingo van Thiel, representing numerous national patient groups from different parts of the world requested to change the name of ‘primary biliary cirrhosis’ to ‘‘correct the inaccuracy’’ and ‘‘remove the cirrhosis stigma’’ as well as all the misunderstanding, disadvantages and discriminations emanating from this misnomer in daily life of the patients. Position Paper This initiative was based on former discussions at a meeting with international patient advocates and medical experts led by Raoul Poupon of France during the EASL International Liver Congress 2014 in London, and based in part on worldwide survey by patient support groups performed among >1200 patients with primary biliary cirrhosis. E-mail discussions among experts in the field before the meeting, as well as intense discussions during the EASL Monothematic Conference in Milan with continual e-mail exchanges after the meeting has led to the widespread view among the vast majority of worldwide experts that; (1) the name ‘primary biliary cirrhosis’ should be changed [as advocated by Dame Sheila Sherlock in 1959]. In addition, the following proposals found broad support among the discussants; (2) the acronym ‘PBC’ should be kept if possible; (3) a simple and short term should be used (imperfection acceptable) as long as the exact pathogenesis of primary biliary cirrhosis remained undefined and, therefore, an ‘ideal’ replacement is not available. In parallel with the growing patient support from Europe and the U.S., several surveys were performed among international experts in the field. Among EASL-selected committee members and senior reviewers of the EASL Guidelines for management of cholestatic liver diseases (n=15), 100% agreed to a name change for primary biliary cirrhosis and 100% voted to keep the abbreviation ‘PBC’. 60% preferred ‘primary biliary cholangitis’, 20% ‘primary biliary cholangiopathy’, and 20% various other names.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ajg.2015.312

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 47

Metadata

Authors
Beuers, U., Gershwin, E. M., Gish, R. G., Invernizzi, P., Jones, D. E. J., Lindor, K., Ma, X., Mackay, I. R., Parés, A., Tanaka, A., Vierling, J. M., & Poupon, R.
Venue
American Journal of Gastroenterology
Published
2015-11
Volume
110
Issue
11
Pages
1536-1538
ISSN
0002-9270 (ISSN-L)
OpenAlex
W2411806713
Cited by
47
References
10
FWCI
3.24
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Changing Nomenclature for PBC: From ‘Cirrhosis’ to ‘Cholangitis’. https://app.cochat.ai/papers/10.1038/ajg.2015.312
The paper
Beuers, U., Gershwin, E. M., Gish, R. G., Invernizzi, P., Jones, D. E. J., Lindor, K., Ma, X., Mackay, I. R., Parés, A., Tanaka, A., Vierling, J. M., & Poupon, R. (2015). Changing Nomenclature for PBC: From ‘Cirrhosis’ to ‘Cholangitis’. American Journal of Gastroenterology. https://doi.org/10.1038/ajg.2015.312

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.